| CAS ID: | 226700-79-4 |
| Molecular Formula: | C25H36N3O9PS |
| Molecular Weight: | 585.6 g/mol |
| Monoisotopic Mass: | 585.191 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | FOSAMPRENAVIR | GW 433908G | TELZIR | FOSAMPRENAVIR CALCIUM | GW 433908A | FOSAMPRENAVIR SODIUM | LEXIVA |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1 | See All |
| InChI Key: | MLBVMOWEQCZNCC-OEMFJLHTSA-N | |
| Smiles: | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)c3ccc(N)cc3 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT01908660 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | July 26, 2013 | Last Verified | November 11, 2015 |
| Sponsor | Valme University Hospital | ||
| PubChem: | 131536 |
| ChEMBL: | CHEMBL1664 |